Skip to main content

Table 3 Summary of case-control analysis of haplotypes associated with paclitaxel response

From: Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines

Gene Haplotype Haplotype Frequencies Case, Control Ratio Counts Case, Control Frequencies Chi Square p Value Odds Ratio L95 U95
GRIK1 GT 0.073 6.3 : 9.7, 2.1 : 97.9 0.394, 0.021 28.362 1.01E-07 30.28 5.56 164.98
ROBO1 AGGT 0.043 4.1 : 7.9, 0.6 : 97.4 0.339, 0.006 28.828 7.91E-08 84.25 5.10 1391.73
SGCD AAC 0.043 4.0 : 12.0, 0.9 : 99.1 0.251, 0.009 19.847 8.39E-06 36.70 3.45 390.22
PTPRD TGGATCCCGT 0.095 8.3 : 7.7, 2.7 : 97.3 0.518, 0.027 38.832 4.62E-10 38.85 8.19 184.29
LPHN2 TTGAGCATCATCTCCCC 0.12 8.0 : 6.0, 5.0 : 89.0 0.571, 0.053 30.902 2.71E-08 23.73 5.91 95.28
  1. This table summarizes the haplotypes that were found more significantly associated with drug response than the originally identified SNP marker alone. Cell lines categorized as cases here are those which were in the resistant group and those categorized as controls are those in the sensitive group. Figure 2 illustrates the relative position of these SNP markers along the genes. Statistics with NA written indicate that the statistic could not be calculated.